Progenics Pharmaceuticals Sets Fourth Quarter and Full-Year 2018 Financial Results and Business Update Call for March 14

NEXT STORY
Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions
PREV STORY
Trinity Biotech announces Quarter 4 and Fiscal Year 2018 Financial Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

CUSM Class of 2023 Focused on Service and Healthcare for All

author_avatar
NASDAQ Market News

Ballad Health Reports Six-Month Results: Better Quality, Strong Financial Performance, and Significant Capital Investments

author_avatar
NASDAQ Market News

VBL Therapeutics Announces Peer-reviewed Publication of Positive Results of Pre-specified Interim Analysis of OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

author_avatar
NASDAQ Market News